AU772222B2 - Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells - Google Patents
Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells Download PDFInfo
- Publication number
- AU772222B2 AU772222B2 AU21039/00A AU2103900A AU772222B2 AU 772222 B2 AU772222 B2 AU 772222B2 AU 21039/00 A AU21039/00 A AU 21039/00A AU 2103900 A AU2103900 A AU 2103900A AU 772222 B2 AU772222 B2 AU 772222B2
- Authority
- AU
- Australia
- Prior art keywords
- growth hormone
- cells
- vivo
- donor
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title claims abstract description 112
- 108010000521 Human Growth Hormone Proteins 0.000 title claims abstract description 112
- 239000000854 Human Growth Hormone Substances 0.000 title claims abstract description 112
- 210000003958 hematopoietic stem cell Anatomy 0.000 title description 14
- 238000000034 method Methods 0.000 claims abstract description 112
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims abstract description 100
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims abstract description 100
- 230000003394 haemopoietic effect Effects 0.000 claims abstract description 47
- 230000001965 increasing effect Effects 0.000 claims abstract description 45
- 102000018997 Growth Hormone Human genes 0.000 claims description 249
- 108010051696 Growth Hormone Proteins 0.000 claims description 249
- 239000000122 growth hormone Substances 0.000 claims description 241
- 210000004027 cell Anatomy 0.000 claims description 212
- 230000001172 regenerating effect Effects 0.000 claims description 150
- 230000011132 hemopoiesis Effects 0.000 claims description 149
- 238000001727 in vivo Methods 0.000 claims description 146
- 210000003040 circulating cell Anatomy 0.000 claims description 118
- 230000001939 inductive effect Effects 0.000 claims description 107
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 70
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 70
- 239000000203 mixture Substances 0.000 claims description 62
- 239000003814 drug Substances 0.000 claims description 60
- 238000002054 transplantation Methods 0.000 claims description 59
- 230000037396 body weight Effects 0.000 claims description 53
- 210000005259 peripheral blood Anatomy 0.000 claims description 53
- 239000011886 peripheral blood Substances 0.000 claims description 53
- 210000004369 blood Anatomy 0.000 claims description 50
- 239000008280 blood Substances 0.000 claims description 50
- 238000011084 recovery Methods 0.000 claims description 35
- 238000011282 treatment Methods 0.000 claims description 35
- 210000000130 stem cell Anatomy 0.000 claims description 24
- 210000001185 bone marrow Anatomy 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 19
- 238000001990 intravenous administration Methods 0.000 claims description 18
- 239000003102 growth factor Substances 0.000 claims description 16
- 210000000265 leukocyte Anatomy 0.000 claims description 16
- 238000007920 subcutaneous administration Methods 0.000 claims description 16
- 102000019034 Chemokines Human genes 0.000 claims description 15
- 108010012236 Chemokines Proteins 0.000 claims description 15
- 102000004127 Cytokines Human genes 0.000 claims description 15
- 108090000695 Cytokines Proteins 0.000 claims description 15
- 241000282414 Homo sapiens Species 0.000 claims description 13
- 241000894007 species Species 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 230000007774 longterm Effects 0.000 claims description 12
- -1 IL-Ial Proteins 0.000 claims description 11
- 210000002960 bfu-e Anatomy 0.000 claims description 10
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 10
- 238000007918 intramuscular administration Methods 0.000 claims description 10
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 9
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 9
- 238000007912 intraperitoneal administration Methods 0.000 claims description 8
- 230000000977 initiatory effect Effects 0.000 claims description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 108010002386 Interleukin-3 Proteins 0.000 claims description 6
- 102100020880 Kit ligand Human genes 0.000 claims description 6
- 101710177504 Kit ligand Proteins 0.000 claims description 6
- 102000000589 Interleukin-1 Human genes 0.000 claims description 5
- 108010002352 Interleukin-1 Proteins 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
- 238000004820 blood count Methods 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 208000001388 Opportunistic Infections Diseases 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 102100039064 Interleukin-3 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 description 36
- 230000000694 effects Effects 0.000 description 29
- 230000009467 reduction Effects 0.000 description 23
- 210000000601 blood cell Anatomy 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 20
- 230000002354 daily effect Effects 0.000 description 18
- 238000001959 radiotherapy Methods 0.000 description 17
- 238000002560 therapeutic procedure Methods 0.000 description 17
- 230000003039 myelosuppressive effect Effects 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 231100000052 myelotoxic Toxicity 0.000 description 14
- 230000002556 myelotoxic effect Effects 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 230000002708 enhancing effect Effects 0.000 description 13
- 210000001772 blood platelet Anatomy 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 238000010322 bone marrow transplantation Methods 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 210000003714 granulocyte Anatomy 0.000 description 10
- 230000001400 myeloablative effect Effects 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 102000036693 Thrombopoietin Human genes 0.000 description 8
- 108010041111 Thrombopoietin Proteins 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 230000001817 pituitary effect Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000001851 biosynthetic effect Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000001332 colony forming effect Effects 0.000 description 6
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 6
- 229960001101 ifosfamide Drugs 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000001483 mobilizing effect Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 208000007502 anemia Diseases 0.000 description 5
- 208000004235 neutropenia Diseases 0.000 description 5
- 206010043554 thrombocytopenia Diseases 0.000 description 5
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 5
- 229960002066 vinorelbine Drugs 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 102000000646 Interleukin-3 Human genes 0.000 description 4
- 210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 description 4
- 238000002617 apheresis Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 230000006240 deamidation Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000009576 somatic growth Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000003462 sulfoxides Chemical class 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002634 anti-blastic effect Effects 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 238000011976 chest X-ray Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000001955 cumulated effect Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229940121366 growth hormone derivative Drugs 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 208000002865 osteopetrosis Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 210000001764 somatotrope Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- BHANCCMWYDZQOR-UHFFFAOYSA-N 2-(methyldisulfanyl)pyridine Chemical compound CSSC1=CC=CC=N1 BHANCCMWYDZQOR-UHFFFAOYSA-N 0.000 description 1
- FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
- VJINKBZUJYGZGP-UHFFFAOYSA-N 3-(1-aminopropylideneamino)propyl-trimethylazanium Chemical compound CCC(N)=NCCC[N+](C)(C)C VJINKBZUJYGZGP-UHFFFAOYSA-N 0.000 description 1
- ONZQYZKCUHFORE-UHFFFAOYSA-N 3-bromo-1,1,1-trifluoropropan-2-one Chemical compound FC(F)(F)C(=O)CBr ONZQYZKCUHFORE-UHFFFAOYSA-N 0.000 description 1
- QHSXWDVVFHXHHB-UHFFFAOYSA-N 3-nitro-2-[(3-nitropyridin-2-yl)disulfanyl]pyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1SSC1=NC=CC=C1[N+]([O-])=O QHSXWDVVFHXHHB-UHFFFAOYSA-N 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- HKTRDWYCAUTRRL-YUMQZZPRSA-N Glu-His Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 HKTRDWYCAUTRRL-YUMQZZPRSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- QCZYYEFXOBKCNQ-STQMWFEESA-N Lys-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCZYYEFXOBKCNQ-STQMWFEESA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- BVZABQIRMYTKCF-JSGCOSHPSA-N Trp-Met Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(O)=O)=CNC2=C1 BVZABQIRMYTKCF-JSGCOSHPSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- HEGWYODBHZZCNR-UHFFFAOYSA-N butane-2,3-dione;2-oxo-2-phenylacetaldehyde Chemical compound CC(=O)C(C)=O.O=CC(=O)C1=CC=CC=C1 HEGWYODBHZZCNR-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- VIMWCINSBRXAQH-UHFFFAOYSA-M chloro-(2-hydroxy-5-nitrophenyl)mercury Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[Hg]Cl VIMWCINSBRXAQH-UHFFFAOYSA-M 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000011188 deamidation reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 201000002802 hemorrhagic cystitis Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000001621 ilium bone Anatomy 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 239000013631 noncovalent dimer Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- YFZOUMNUDGGHIW-UHFFFAOYSA-M p-chloromercuribenzoic acid Chemical compound OC(=O)C1=CC=C([Hg]Cl)C=C1 YFZOUMNUDGGHIW-UHFFFAOYSA-M 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- HMFAQQIORZDPJG-UHFFFAOYSA-N phosphono 2-chloroacetate Chemical compound OP(O)(=O)OC(=O)CCl HMFAQQIORZDPJG-UHFFFAOYSA-N 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98124834A EP1016413A1 (en) | 1998-12-30 | 1998-12-30 | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| EP98124834 | 1998-12-30 | ||
| PCT/EP1999/010470 WO2000040260A1 (en) | 1998-12-30 | 1999-12-30 | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004203355A Division AU2004203355B2 (en) | 1998-12-30 | 2004-07-22 | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2103900A AU2103900A (en) | 2000-07-24 |
| AU772222B2 true AU772222B2 (en) | 2004-04-22 |
Family
ID=8233268
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU21039/00A Ceased AU772222B2 (en) | 1998-12-30 | 1999-12-30 | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| AU2004203355A Ceased AU2004203355B2 (en) | 1998-12-30 | 2004-07-22 | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004203355A Ceased AU2004203355B2 (en) | 1998-12-30 | 2004-07-22 | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20060029581A1 (https=) |
| EP (3) | EP1016413A1 (https=) |
| JP (1) | JP4808316B2 (https=) |
| AT (1) | ATE342064T1 (https=) |
| AU (2) | AU772222B2 (https=) |
| BR (1) | BR9916726A (https=) |
| CA (1) | CA2354194A1 (https=) |
| CY (1) | CY1107603T1 (https=) |
| DE (1) | DE69933581T2 (https=) |
| DK (1) | DK1140149T3 (https=) |
| ES (1) | ES2275359T3 (https=) |
| IL (2) | IL143994A0 (https=) |
| PT (1) | PT1140149E (https=) |
| SI (1) | SI1140149T1 (https=) |
| WO (1) | WO2000040260A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003535144A (ja) * | 2000-06-07 | 2003-11-25 | アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ | 多能性造血幹細胞の流動を刺激するヒト成長ホルモン |
| CA2417356A1 (en) | 2000-08-01 | 2002-02-07 | Yissum Research Development Company | Directed differentiation of embryonic cells |
| ES2380009T3 (es) * | 2001-07-31 | 2012-05-07 | Genzyme Global S.A.R.L. | Métodos para movilizar las células madre/progenitoras |
| CA2540529C (en) * | 2003-10-03 | 2012-03-13 | Vib Vzw | Means and methods for the recruitment and identification of stem cells |
| JP2005289837A (ja) * | 2004-03-31 | 2005-10-20 | Juntendo | 骨髄細胞誘導剤の製造方法及び製造装置 |
| US7816320B2 (en) * | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
| JP2013515081A (ja) * | 2009-12-21 | 2013-05-02 | アンブルックス，インコーポレイテッド | 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5649904A (en) * | 1988-10-07 | 1997-07-22 | Sandoz Ltd. | Method of treating cancer with a fully myeloablative regimen of chemotherapy, radiation or both |
| US5199942A (en) * | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| EP0563485A1 (en) * | 1992-03-30 | 1993-10-06 | Schering-Plough | In vitro generation of human dendritic cells and uses thereof |
| DE69430059T2 (de) * | 1993-06-15 | 2002-11-14 | British Biotech Pharmaceuticals Ltd., Cowley | Freisetzung und Mobilisierung hämatopoietischer Zellen |
| JPH07101877A (ja) * | 1993-10-04 | 1995-04-18 | Mitsui Toatsu Chem Inc | 血小板減少症治療剤 |
| DE69433967D1 (de) * | 1993-10-06 | 2004-09-30 | Univ Florida | Stammzellen-proliferations-faktor |
| JPH0892001A (ja) * | 1994-09-26 | 1996-04-09 | Asahi Medical Co Ltd | 細胞集団の保存方法 |
| EP0871458B1 (en) * | 1995-07-21 | 2002-11-20 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment |
| EP0877795A4 (en) * | 1996-01-16 | 2003-03-05 | Depuy Orthopaedics Inc | INSULATION OF PROCUREMENT CELLS FROM HEMATOPOIETIC AND NON-HEMATOPOIETIC TISSUES AND THEIR USE |
| JP4042925B2 (ja) * | 1996-11-20 | 2008-02-06 | シスメックス株式会社 | 幼若白血球の分類計数法 |
| JPH10295369A (ja) * | 1997-02-26 | 1998-11-10 | Japan Tobacco Inc | 造血幹細胞の製造方法 |
| SE9804064D0 (sv) * | 1998-11-25 | 1998-11-25 | A & Science Invest Ab | Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
| DE69919969T2 (de) * | 1998-12-17 | 2005-09-29 | Applied Research Systems Ars Holding N.V. | Humanes Wachstumshormon zur Stimulierung der Hämatopoese und der Immunrekonstitution nach hämatopoetischer Stammzelltransplantation beim Menschen |
| JP2003535144A (ja) * | 2000-06-07 | 2003-11-25 | アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ | 多能性造血幹細胞の流動を刺激するヒト成長ホルモン |
| US7220407B2 (en) * | 2003-10-27 | 2007-05-22 | Amgen Inc. | G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction |
-
1998
- 1998-12-30 EP EP98124834A patent/EP1016413A1/en not_active Withdrawn
-
1999
- 1999-12-30 WO PCT/EP1999/010470 patent/WO2000040260A1/en not_active Ceased
- 1999-12-30 DK DK99965579T patent/DK1140149T3/da active
- 1999-12-30 PT PT99965579T patent/PT1140149E/pt unknown
- 1999-12-30 IL IL14399499A patent/IL143994A0/xx unknown
- 1999-12-30 SI SI9930937T patent/SI1140149T1/sl unknown
- 1999-12-30 JP JP2000592015A patent/JP4808316B2/ja not_active Expired - Fee Related
- 1999-12-30 AT AT99965579T patent/ATE342064T1/de active
- 1999-12-30 ES ES99965579T patent/ES2275359T3/es not_active Expired - Lifetime
- 1999-12-30 EP EP06021178A patent/EP1779865A1/en not_active Withdrawn
- 1999-12-30 DE DE69933581T patent/DE69933581T2/de not_active Expired - Lifetime
- 1999-12-30 CA CA002354194A patent/CA2354194A1/en not_active Abandoned
- 1999-12-30 AU AU21039/00A patent/AU772222B2/en not_active Ceased
- 1999-12-30 BR BR9916726-3A patent/BR9916726A/pt not_active Application Discontinuation
- 1999-12-30 EP EP99965579A patent/EP1140149B1/en not_active Expired - Lifetime
-
2001
- 2001-06-26 IL IL143994A patent/IL143994A/en not_active IP Right Cessation
-
2004
- 2004-07-22 AU AU2004203355A patent/AU2004203355B2/en not_active Ceased
-
2005
- 2005-09-29 US US11/237,876 patent/US20060029581A1/en not_active Abandoned
-
2007
- 2007-01-08 CY CY20071100021T patent/CY1107603T1/el unknown
Non-Patent Citations (2)
| Title |
|---|
| MURHY WJ ET AK, BLOOD, 15 SEPT 1992, P1443-1447 * |
| TIAN ZG ET AL, STEM CELLS, 1998, 16(3), P 193-9 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000040260A1 (en) | 2000-07-13 |
| AU2103900A (en) | 2000-07-24 |
| JP2002534393A (ja) | 2002-10-15 |
| US20060029581A1 (en) | 2006-02-09 |
| JP4808316B2 (ja) | 2011-11-02 |
| IL143994A0 (en) | 2002-04-21 |
| DE69933581T2 (de) | 2007-06-21 |
| AU2004203355B2 (en) | 2007-05-17 |
| EP1140149B1 (en) | 2006-10-11 |
| EP1779865A1 (en) | 2007-05-02 |
| ATE342064T1 (de) | 2006-11-15 |
| EP1016413A1 (en) | 2000-07-05 |
| SI1140149T1 (sl) | 2007-02-28 |
| DK1140149T3 (da) | 2007-02-19 |
| IL143994A (en) | 2009-06-15 |
| CY1107603T1 (el) | 2013-03-13 |
| AU2004203355A1 (en) | 2004-08-19 |
| DE69933581D1 (de) | 2006-11-23 |
| EP1140149A1 (en) | 2001-10-10 |
| BR9916726A (pt) | 2001-09-11 |
| CA2354194A1 (en) | 2000-07-13 |
| PT1140149E (pt) | 2007-01-31 |
| ES2275359T3 (es) | 2007-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1286689B1 (en) | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells | |
| AU2001281800A1 (en) | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells | |
| US5126325A (en) | Method for treating thrombocytopenia | |
| EP0289186A2 (en) | Process for increasing the growth rate and enhancing the feed efficiency of meat producing livestock | |
| US6013067A (en) | Methods for increasing hematopoietic cells | |
| JP2005336202A (ja) | マクロファージ炎症蛋白変種 | |
| CA2170979A1 (en) | Increase in hematopoietic progenitor cells in peripheral blood by transforming growth factor beta | |
| AU772222B2 (en) | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells | |
| AU712235B2 (en) | Method of mobilizing hematopoietic stem cells | |
| AU776181B2 (en) | Combined treatment of multiple sclerosis | |
| US6348444B1 (en) | Human growth hormone to stimulate hematopoiesis and immune reconstitution after hematopoietic stem cell transplantation in humans | |
| MXPA01006681A (en) | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells | |
| JPH08127539A (ja) | ヒトｉｌ−１１を含有する末梢血幹細胞増加剤 | |
| EP1033997B1 (en) | Method of mobilizing hematopoietic stem cells | |
| van Miere et al. | The effects of ACTH, prednisolone and Escherichia coli endotoxin on some clinical haematological and blood biochemical parameters in dwarf goats | |
| Finley | Overview of Biotechnology in Health Care | |
| CN1205708A (zh) | 动员造血干细胞的方法 | |
| MXPA98003217A (en) | Method of mobilization of hematopoyetic mother cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |